Psychotic patients who used cannabinoids showed different inflammation patterns linked to symptom severity

Among 119 acutely psychotic inpatients, those who tested positive for cannabinoids showed a different relationship between inflammation (IL-6) and psychosis severity than cannabinoid-negative patients, and synthetic cannabinoid users were more likely to need emergency sedation.

Gibson, Claire L et al.·Psychiatry research·2020·Moderate EvidenceCross-Sectional
RTHC-02572Cross SectionalModerate Evidence2020RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Cross-Sectional
Evidence
Moderate Evidence
Sample
N=60

What This Study Found

While PANSS psychosis scores were similar between groups, cannabinoid-positive patients showed a negative correlation between IL-6 levels and psychosis severity, meaning higher inflammation was associated with lower symptom scores. Synthetic cannabinoid-positive patients were more likely to require emergency agitation medication.

Key Numbers

59 cannabinoid-positive vs. 60 cannabinoid-negative patients. IL-6 negatively correlated with PANSS total (p=0.040), positive (p=0.035), and negative (p=0.024) subscales in cannabinoid-positive group.

How They Did This

Cross-sectional study comparing 59 acutely psychotic inpatients with positive cannabinoid toxicology (natural and/or synthetic) to 60 patients with negative cannabinoid toxicology. Inflammatory markers and PANSS scores were measured.

Why This Research Matters

The inverse relationship between IL-6 and psychosis severity in cannabinoid users suggests that cannabinoids may alter the typical inflammation-psychosis connection, potentially through immunomodulatory effects.

The Bigger Picture

If cannabinoids modify the inflammatory component of psychosis, this could explain why some cannabinoid-using patients present differently from non-using patients and might respond differently to anti-inflammatory interventions.

What This Study Doesn't Tell Us

Cross-sectional design cannot establish causation. The cannabinoid-positive group included both natural and synthetic users. IFN-gamma differences were not significant after adjusting for covariates.

Questions This Raises

  • ?Why is the IL-6-psychosis relationship reversed in cannabinoid users?
  • ?Do synthetic cannabinoids pose a greater agitation risk than natural cannabis?
  • ?Could anti-inflammatory treatments work differently in cannabinoid-using psychotic patients?

Trust & Context

Key Stat:
IL-6 negatively correlated with psychosis severity in cannabinoid users
Evidence Grade:
Moderate: controlled comparison with objective toxicology, though cross-sectional and modest sample size.
Study Age:
Published in 2020 in Psychiatry Research.
Original Title:
Cannabinoid use in psychotic patients impacts inflammatory levels and their association with psychosis severity.
Published In:
Psychiatry research, 293, 113380 (2020)
Database ID:
RTHC-02572

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

A snapshot of a population at one point in time.

What do these levels mean? →

Frequently Asked Questions

Why did cannabinoid users need more emergency medication?

Particularly those who tested positive for synthetic cannabinoids were more likely to require PRN (as-needed) medication for agitation in the emergency room, suggesting synthetic cannabinoids may produce more acute behavioral disturbance.

What does the IL-6 finding mean?

Normally, higher IL-6 (an inflammatory marker) correlates with worse psychosis. In cannabinoid-positive patients, this relationship was reversed, possibly because cannabinoids have immunomodulating properties that change how inflammation relates to symptoms.

Read More on RethinkTHC

Cite This Study

RTHC-02572·https://rethinkthc.com/research/RTHC-02572

APA

Gibson, Claire L; Bassir Nia, Anahita; Spriggs, Sharron A; DeFrancisco, Daniel; Swift, Amy; Perkel, Charles; Zhong, Xiaobo; Mazumdar, Madhu; Fernandez, Nicolas; Patel, Manishkumar; Kim-Schulze, Seunghee; Hurd, Yasmin L. (2020). Cannabinoid use in psychotic patients impacts inflammatory levels and their association with psychosis severity.. Psychiatry research, 293, 113380. https://doi.org/10.1016/j.psychres.2020.113380

MLA

Gibson, Claire L, et al. "Cannabinoid use in psychotic patients impacts inflammatory levels and their association with psychosis severity.." Psychiatry research, 2020. https://doi.org/10.1016/j.psychres.2020.113380

RethinkTHC

RethinkTHC Research Database. "Cannabinoid use in psychotic patients impacts inflammatory l..." RTHC-02572. Retrieved from https://rethinkthc.com/research/gibson-2020-cannabinoid-use-in-psychotic

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.